Get the Stockscreener App
22.56
0.00%
0.0308
Denali Therapeutics Inc stock is traded at $22.56, with a volume of 301.80K.
It is up +0.00% in the last 24 hours and up +6.37% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$22.53
Open:
$22.41
24h Volume:
301.80K
Relative Volume:
0.34
Market Cap:
$3.24B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-7.9161
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-3.30%
1M Performance:
+6.37%
6M Performance:
+3.92%
1Y Performance:
+32.92%
1-Day Range:
$22.11
$23.04
1-Week Range:
$21.55
$24.34
52-Week Range:
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8548
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
22.57 | 3.24B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.19 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - Zacks Investment Research
Short Interest in Denali Therapeutics Inc. (NASDAQ:DNLI) Grows By 5.1% - MarketBeat
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - Marketscreener.com
Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa - Marketscreener.com
Where are the Opportunities in (DNLI) - Stock Traders Daily
Leerink Partnrs Has Negative Outlook of DNLI FY2025 Earnings - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.2%Should You Sell? - MarketBeat
Zacks Research Has Bearish Estimate for DNLI FY2024 Earnings - MarketBeat
Denali Gains 26.6% in a Year: How Should You Play the Stock? - MSN
Denali Therapeutics Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - Simply Wall St
What is Leerink Partnrs’ Forecast for DNLI FY2025 Earnings? - Defense World
Zacks Research Has Negative Outlook of DNLI FY2024 Earnings - Defense World
The Goldman Sachs Group Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $40.00 - MarketBeat
Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire
Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference - StockTitan
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™ - Yahoo Finance
The Goldman Sachs Group Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3%Time to Sell? - MarketBeat
How To Trade (DNLI) - Stock Traders Daily
Cantor Fitzgerald Weighs in on DNLI FY2025 Earnings - Defense World
Analysts Set Expectations for DNLI FY2025 Earnings - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Update - Defense World
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
JPMorgan Chase & Co. Purchases 14,324 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Denali Therapeutics sees cash runway into 2028 - MSN
Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 9.8%Still a Buy? - MarketBeat
Denali Therapeutics' (DNLI) Outperform Rating Reaffirmed at William Blair - MarketBeat
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints - MSN
Denali Therapeutics Announces Key Anticipated 2025 - GlobeNewswire
Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025 - StockTitan
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - The Manila Times
Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome - MSN
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail - BioSpace
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock By Investing.com - Investing.com Nigeria
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More - MSN
Denali Therapeutics director Steve Krognes sells $69,484 in stock By Investing.com - Investing.com Australia
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI) - Seeking Alpha
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock By Investing.com - Investing.com South Africa
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
175,673 |
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '25 |
Sale |
20.22 |
12,255 |
247,796 |
247,215 |
| Schuth Alexander O. | COFO and Secretary |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
244,308 |
| Watts Ryan J. | President and CEO |
Jan 06 '25 |
Sale |
20.22 |
29,266 |
591,759 |
260,721 |
| Watts Ryan J. | President and CEO |
Jan 07 '25 |
Sale |
20.81 |
7,650 |
159,196 |
253,071 |
| Krognes Steve E. | Director |
Jan 07 '25 |
Sale |
20.81 |
3,339 |
69,485 |
25,757 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):